Dosage Forms

Articles

Valneva will manufacture the Sabin vaccine strains for clinical trials in its manufacturing facility in Solna, Sweden, using Batavia’s process.

Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development

Catalent will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Anagni, Italy, for the large-scale commercial manufacturing of the University of Oxford’s adenovirus vector-based COVID-19 vaccine candidate.

Catalent to Partner with AstraZeneca for COVID-19 Vaccine

Oxford Biomedica, has signed a collaboration agreement with the not-for-profit organization, the Vaccines Manufacturing and Innovation Centre, to provide the UK with its first strategic vaccine development and advanced manufacturing capability.

Oxford Biomedica Signs Agreement with Vaccines Manufacturing and Innovation Centre

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Dyadic International Selected for COVID-19 Vaccine Candidate Development

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility. 

Catalent Partners with Spicona for COVID-19 Vaccine Development

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate. 

Novavax Secures $60 Million in Government Funds

The European Commission is pledging EUR 300 million (US$339 million) to Gavi for vaccines for infectious diseases, in addition to an earlier pledge of more than EUR 1.5 billion (US$1.7 billion) made on May 4, 2020.

EC Pledges Nearly $340 Million Additional Vaccine Funding to Gavi

The new vaccine would be made with a Newcastle disease virus vector that expresses the immunogenic spike protein of SARS-CoV-2

Netherlands Partnership to Develop an Intranasal COVID-19 Vaccine

The Gavi advance market commitment for COVID-19 vaccines is a new financing instrument aimed at incentivizing vaccine manufacturers to produce sufficient and affordable quantities of COVID-19 vaccines.

Gavi Launches $2-Billion COVID-19 Vaccine Funding Initiative

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Despite the clear danger of COVID-19 to global health, vaccine opponents have gained ground, as fearful populations lose faith in the capabilities of industry and government to protect public health.

